• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by DiaMedica Therapeutics Inc.

    11/13/25 4:31:40 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    S-8 1 dmtp20251113_s8.htm FORM S-8 dmtp20251113_s8.htm

    As filed with the Securities and Exchange Commission on November 13, 2025.

    Registration No.          

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C. 20549

     

    Form S-8

     

    REGISTRATION STATEMENT UNDER THE
    SECURITIES ACT OF 1933

     

    DIAMEDICA THERAPEUTICS INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    British Columbia, Canada

     

    Not Applicable

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification No.)

         

    301 Carlson Parkway, Suite 210
    Minneapolis, Minnesota

     

    55305

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    DiaMedica Therapeutics Inc.
    2021 Employment Inducement Plan

    (Full Title of the Plan)

     

     

    Rick Pauls

    President and Chief Executive Officer

    DiaMedica Therapeutics Inc.

    301 Carlson Parkway, Suite 210

    Minneapolis, Minnesota 55305

    (Name and Address of Agent for Service)

     

     

    Telephone number, including area code, of agent for service: (763) 496-5454

     


    Copies to:

    Jonathan R. Zimmerman

    Joshua L. Colburn

    Faegre Drinker Biddle & Reath LLP

    2200 Wells Fargo Center

    90 South Seventh Street

    Minneapolis, Minnesota 55402‑3901

    Keith Inman

    Pushor Mitchell LLP

    301 – 1665 Ellis Street

    Kelowna, British Columbia

    Canada

    V1Y 2B3

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer ☐

    Accelerated Filer ☐

    Non‑accelerated Filer ☑

    Smaller Reporting Company ☑

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    DIAMEDICA THERAPEUTICS INC.

     

    STATEMENT PURSUANT TO GENERAL INSTRUCTION E
    TO FORM S-8 “REGISTRATION OF ADDITIONAL SECURITIES”

     

    This Registration Statement on Form S-8 (the “Registration Statement”) relates to the registration of 1,000,000 voting common shares, no par value per share (“Common Shares”), of DiaMedica Therapeutics Inc. (the “Company”) issuable to eligible individuals pursuant to awards granted under the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (the “Plan”). The Company previously filed a registration statement on Form S-8 (File No. 333-263543) relating to the Plan (the “Initial Registration Statement”).

     

    On July 31, 2025, the Company’s Board of Directors amended the Plan, pursuant to which the Company reserved an additional 1,000,000 Common Shares to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company, as an inducement to the individual’s entry into employment with the Company within the meaning of Nasdaq Listing Rule 5635(c)(4). The Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, or other stock-based awards. The Plan was initially adopted and subsequently amended and restated without shareholder approval in reliance upon Nasdaq Listing Rule 5635(c)(4).

     

    Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement, together with all exhibits filed therewith or incorporated therein by reference, are incorporated herein by reference except to the extent that such information is superseded by the Items appearing below.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.    Exhibits.

     

    Exhibit

    Number

     

    Description of Exhibit

    4.1

     

    Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025 (incorporated by reference to Exhibit 3.1 to quarterly report on Form 10-Q for the quarter ended June 30, 2025)

    4.2

     

    Amended and Restated Articles of DiaMedica Therapeutics Inc. dated May 17, 2023 (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed May 18, 2023)

    5.1+

     

    Opinion of  Pushor Mitchell LLP

    23.1+

     

    Consent of Baker Tilly US, LLP, independent registered public accounting firm for the Registrant

    23.2+

     

    Consent of  Pushor Mitchell LLP (included in Exhibit 5.1)

    24+

     

    Powers of Attorney (included with signatures)

    99.1

     

    Amended and Restated 2021 Employment Inducement Incentive Plan dated July 31, 2025 (incorporated by reference to Exhibit 10.3 to quarterly report on Form 10-Q for the period ended September 30, 2025)

    107+

     

    Filing Fee Table

     


    + Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Minneapolis, State of Minnesota , on November 13, 2025.

     

    DIAMEDICA THERAPEUTICS INC.

       

    By:

     

    /s/ Rick Pauls

       

    Name: Rick Pauls

       

    Title: President and Chief Executive Officer

     

    POWERS OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Rick Pauls and Scott Kellen, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Registration Statement filed herewith and any and all amendments to said Registration Statement (including post-effective amendments), and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

     

    Signature

     

    Title

     

    Date

             

    /s/ Rick Pauls

     

    President, Chief Executive Officer and Director

     

    November 13, 2025

    Rick Pauls

     

    (principal executive officer)

       
             

    /s/ Scott Kellen

     

    Chief Financial Officer and Secretary

     

    November 13, 2025

    Scott Kellen

     

    (principal financial and accounting officer)

       
             

    /s/ Michael Giuffre, M.D.

     

    Director

     

    November 13, 2025

    Michael Giuffre, M.D.

           
             

    /s/ Richard Kuntz, M.D.

     

    Director

     

    November 13, 2025

    Richard Kuntz, M.D.

           
             

    /s/ Tanya N. Lewis

     

    Director

     

    November 13, 2025

    Tanya N. Lewis

           
             

    /s/ Daniel O’Connor

     

    Director

     

    November 13, 2025

    Daniel O’Connor

           
             

    /s/ James Parsons

     

    Chairman of the Board, Director

     

    November 13, 2025

    James Parsons

           
             

    /s/ Charles Semba, M.D.

     

    Director

     

    November 13, 2025

    Charles Semba, M.D.

           

     

     
    Get the next $DMAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    11/14/2025Overweight
    Cantor Fitzgerald
    10/30/2025Buy
    TD Cowen
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on DiaMedica Therapeutics

    Cantor Fitzgerald resumed coverage of DiaMedica Therapeutics with a rating of Overweight

    11/14/25 12:00:36 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on DiaMedica Therapeutics

    TD Cowen initiated coverage of DiaMedica Therapeutics with a rating of Buy

    10/30/25 7:43:04 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

    H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

    10/7/24 7:50:42 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027 Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutica

    11/12/25 4:30:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. Mr. Pauls will deliver a corporate presentation and participate in one-on-one investor meetings during the conference. Details Jefferies Global Healthcare Conference in London Time below is listed in Greenwich Mean Time (GMT) Corporate Presentation: Date: Thursday, November 20, 2025 Time: 10:00-10:25 AM About DiaMedica Therapeutics Inc.

    11/10/25 8:15:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 13, 2025 Time: 8:00 AM ET /7:00 AM CT Web access: https://app.webinar.net/MlAxZJky3Q7 Dial In: (888) 880-3330 Conference ID: 9449322

    11/6/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Marketing Officer Krop Julie

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    11/3/25 4:32:02 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Krop Julie

    3 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    11/3/25 4:31:24 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,958,107 worth of shares (1,000,000 units at $5.96) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    9/4/25 2:29:35 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    SEC Filings

    View All

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form S-8 filed by DiaMedica Therapeutics Inc.

    S-8 - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    11/13/25 4:31:40 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by DiaMedica Therapeutics Inc.

    10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    11/12/25 4:33:20 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

    11/12/25 4:31:37 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,958,107 worth of shares (1,000,000 units at $5.96) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    9/4/25 2:29:35 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Stahlberg Jan bought $5,400,000 worth of shares (1,542,857 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 6:54:18 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Von Koch Thomas bought $9,999,997 worth of shares (2,857,142 units at $3.50) (SEC Form 4)

    4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

    7/25/25 5:49:44 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our te

    8/6/25 8:00:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

    2/24/25 8:30:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

    SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    7/8/24 5:23:49 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:12:06 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

    6/27/23 4:11:32 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMAC
    Financials

    Live finance-specific insights

    View All

    DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person pre-IND meeting with U.S. FDA to Discuss Plans for the Initiation of a U.S. Phase 2 DM199 Study in Preeclampsia AIS enrollment in ReMEDy2 Phase 2/3 Trial Nearing 50% of Target of 200 Patients for the Interim Analysis Expected in 2H 2026 $55 million in Cash, Cash Equivalents and Investments, Anticipated Runway into 2H 2027 Conference Call and Webcast on November 13 at 8:00 AM ET / 7:00 AM CT DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutica

    11/12/25 4:30:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on Thursday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 13, 2025 Time: 8:00 AM ET /7:00 AM CT Web access: https://app.webinar.net/MlAxZJky3Q7 Dial In: (888) 880-3330 Conference ID: 9449322

    11/6/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement Extends Cash Runway into H2 2027 and Enables Acceleration of Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline Enrollment for ReMEDy2 Phase 2/3 Trial Progressing with Interim Data Anticipated in Q2 2026 Inclusion in the Russell 2000® and 3000® Indexes Appointment of Julie Krop, MD, to Chief Medical Officer Conference Call and Webcast August 13 at 8:00 AM Eastern Time / 7:00 AM Central Time DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage

    8/12/25 4:15:00 PM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care